Dr. Larry L. Kestin

  • MD, FACR
  • Radiation Oncologist
  • Spoken languages English

Overview

Career Positions

Current position(s)

  • GenesisCare - Medical Director, Michigan Region, Farmington Hills, MI

Past position(s)

  • GenesisCare - National Director of Thoracic and Lung Services, Farmington Hills, MI
  • Oakland University William Beaumont School of Medicine - Full Professor, Royal Oak, MI
  • Oakland Community College - Full Professor, Bloomfield Hills, MI

Education

Universities

  • University of Missouri, BS, Computer Science, Columbia, MO
  • University of Kansas School of Medicine, Kansas City, KS

Residencies

  • William Beaumont Hospital, Radiation Oncology, Chief Resident, Royal Oak, MI

Internships

  • William Beaumont Hospital, Rotating Program, Royal Oak, MI

Expertise And Interests

Interests

  • Lung / Thoracic, Lymphoma, Sarcoma, Prostate, GenitoUrinary Malignancies, Breast

Accomplishments

Awards and honors

  • Best Doctors in America &

Publications

  • Stereotactic image-guided lung radiotherapy (SBRT) for clinical early-stage NSCLC: A long-term report from a multi-institutional database of patients treated with or without a pathologic diagnosis.
  • Cardiac Dose in Locally Advanced Lung Cancer: Results from a Statewide Consortium.
  • In Vivo Verification and Daily and Cumulative Dose Recalculation for Helical Tomotherapy: Multi Center Validation Based on Greater than 150,000 Daily Fractions Delivered
Expand Publications
View 1 more

Presentations

Z091420168

E. Arrojo, E. Fernandez, L. Kestin, A. Martinez, 2016, ACRO

View Presentation

Z083120151

Martinez A, Olivera G, Ghilezan M, Forman J, Kestin L, Finkelstein S, Mo X, Key S, Mantz C, Fernandez E, Galmarini D, et al., 2015, ASTRO Annual Meeting

View Presentation

Z061520151

Kestin L, Fernandez E, Mantz C, Olivera G, Mo X, Key S, Finkelstein SE, Martinez A, Galmarini D., 2015, ASTRO Annual Meeting

View Presentation
Expand Presentations
View 1 more

Clinical studies

Primary Objective The primary goal of this study is to determine whether, in men with postprostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.

View Study

Larry Kestin's Reviews

Overall

based on 76 Ratings 14 Comments

2021

Dr. perhaps could have spent more than a minute in consultation, even though I had no questions. Gave me the result of my blood work and that was it. Could have done that over the phone.

2021

Nothing, these docs are the best.

2021

Nothing, the visit was great. I feel confident being in their hands.

2021

Nothing! Everything was great. Couldn't ask for a better experience.

Read More

Ratings and Comments Powered by NRC Health